Analysts Stance: United Therapeutics Corporation (NASDAQ:UTHR)
United Therapeutics Corporation (NASDAQ:UTHR)’s shares have shed more than 28% year-to-date, making its valuation attractive, according to Credit Suisse. Martin Auster upgraded United Therapeutics from Neutral to Outperform and raised the price target from $98 to $101.
The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the UTHR is 0.10%. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments.
Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that UTHR. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public. The insider transactions of the company (6-month change in insider ownerships) for the United Therapeutics Corporation (NASDAQ:UTHR) is -77.29%.
Institutional ownership is the amount of a United Therapeutics Corporation (NASDAQ:UTHR)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it, and the Institutional ownership for the UTHR is 0.49%.
a Healthcare sector firm, United Therapeutics Corporation (NASDAQ:UTHR) stock edged up 5.11% on Monday and when day-trade ended the stock finally concluded at $82.05 and number of shares that changed hands during the day are 836764. The number of shares UTHR stock currently held by all its shareholders are 43.22 and floated shares, the number of shares are available for trading in an open market on last trading day are 43.04. The average volume of shares for 3 months is 741.52 and UTHR stock value has moved between $75.97 – 130.24 in last one year.
The United Therapeutics Corporation (NASDAQ:UTHR)’s latest earnings date is 7/31/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The valuable gross margin for United Therapeutics Corporation (NASDAQ:UTHR) is 89.10% and the profit margin is -9.40% and the stock has gained -24.66% in 2019 to date.
U.S. traded shares of United Therapeutics Corporation (NASDAQ:UTHR)’s monthly stock performance is -2.29%, the quarterly performance is -30.42%, the half year performance is calculated as -21.89%. The yearly performance of UTHR is -26.39%.
The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The United Therapeutics Corporation (NASDAQ:UTHR) weekly volatility is measured as 2.61% and monthly volatility measured as 3.14%.
Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. UTHR return on assets is -4.30%, the return on equity (ROE) of the United Therapeutics Corporation (NASDAQ:UTHR) is -5.70%, while the most important return on investment is calculates as a percentage and is typically used for personal financial decisions, and UTHR return on investment is 19.00%.
The price to sales ratio is 2.21, and price to book ratio is 1.53, price to cash per share ration is 2.21.
Analysts mean target price for United Therapeutics Corporation (NASDAQ:UTHR) is $122.67 while analysts mean recommendation is 2.90. The current share price indicates that stock is -36.88% away from its one year high and is moving 8.36% ahead of its 52-week low. UTHR’s distance from 20 day simple moving average is 2.89% and distance from 50-Day simple moving average is -7.41%.